A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (≤18 Years to ≥64 Years of Age).

NCT00320346 Phase 2 COMPLETED

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic. This study will test the safety and immunogenicity of a H5N1 Pandemic Influenza Vaccine in healthy adults. The Study will also assess Lot to Lot consistency of the Pandemic Influenza Vaccine.

Details

Lead sponsor	Seqirus
Phase	Phase 2
Status	COMPLETED
Enrolment	400
Start date	2006-07
Completion	2006-09

Conditions

• Influenza

Interventions

• Pandemic Influenza Vaccine

Primary outcomes

• Safety and Immunogenicity

Countries

Australia